IDXG首席执行官Thomas Burnell表示,随着交易的完成,公司的运营现金流预计每年将增加近500万美元,且将把出售所得用于满足营运资金需求,并用于投资发展分子诊断业务。
$药明康德(SH603259)$ $泰格医药(SZ...查看全文
不乱下2019-04-25 11:27
$Interpace诊断(IDXG)$ 从事于美国甲状腺癌/胰腺癌组织LDT基因诊断服务(不是液体活检),这是一家LDT服务商。 IDXG的主要产品都是并购过来的资产,所以这家公司的定位就是一个商业化公司而不是一个技术公司。 按照公司的说法,公司在甲状腺癌组织基因诊断服务方面技术上还是领先的,而胰腺癌好像...查看全文
$Interpace Diagnostics Group, Inc.(IDXG)$ 8-K - Current report: i Filed: 2017-07-27 AccNo: 0001493152-17-008209 Size: 49 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Interpace Diagnostics Group, Inc.(IDXG)$ CORRESP [Cover] - Correspondence Filed: 2017-06-14 AccNo: 0001493152-17-006648 Size: 15 KB 网页链接
$Interpace Diagnostics Group, Inc.(IDXG)$ CORRESP [Cover] - Correspondence Filed: 2017-06-14 AccNo: 0001493152-17-006646 Size: 17 KB 网页链接
$Interpace Diagnostics Group, Inc.(IDXG)$ CORRESP [Cover] - Correspondence Filed: 2017-06-13 AccNo: 0001493152-17-006564 Size: 15 KB 网页链接
$Interpace Diagnostics Group, Inc.(IDXG)$ CORRESP [Cover] - Correspondence Filed: 2017-06-13 AccNo: 0001493152-17-006545 Size: 17 KB 网页链接
$Interpace Diagnostics(IDXG)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2017-06-23 AccNo: 0000919574-17-004998 Size: 106 KB 网页链接
$Interpace Diagnostics(IDXG)$ 8-K - Current report Filed: 2017-06-21 AccNo: 0001493152-17-006961 Size: 881 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Interpace Diagnostics(IDXG)$ S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] Filed: 2017-06-16 AccNo: 0001493152-17-006723 Size: 111 KB 网页链接
$Interpace Diagnostics(IDXG)$ S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 Filed: 2017-06-13 AccNo: 0001493152-17-006560 Size: 201 KB 网页链接
$Interpace Diagnostics(IDXG)$ S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 Filed: 2017-06-13 AccNo: 0001493152-17-006543 Size: 20 MB 网页链接